|Videos|September 29, 2018

Recommending the Flu Shot to Patients Vulnerable to Infection

Mindy Smith, BSPharm, RPh, provides tips for recommending the flu shot to patients who are more likely to get the flu.

Segment Description: Mindy Smith, BSPharm, RPh, VP of Pharmacy Practice Innovation, PrescribeWellness provides tips for recommending the flu shot to patients who are more likely to get the flu.

Interview transcript: (modified slightly for readability):

“I think related to high-risk patient population, it’s really important to communicate to that individual patient about how they’re at such a high risk related to being immunocompromised, which makes them more susceptible to getting any type of illness.

Anytime that you can protect yourself with, armor yourself with vaccinations to lower that risk, because you’re in that population that has that higher potential, it’s so important to have those conversations with every single one of those patients.

Because those are the patients who are the most vulnerable, you end up in the hospital, and/or can’t recover from, say, for example, pneumonia, and have a much more difficult time if they were to get that infection.”


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.